Clinical Podcasts Archive

Important:

Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online.

UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

This archive contains podcasts more than six months old. Find our most recent episodes at UpToDate Talk clinical podcasts or, to be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes.

Spirometry and asthma diagnosis; Baricitinib for the treatment of rheumatoid arthritis

Date Released: May 17 2017

This episode features Dr. Christopher Fanta, discussing the role of spirometry in the diagnosis of asthma; and Dr. James O’Dell, discussing baricitinib, a promising oral agent for the treatment of rheumatoid arthritis. Dr. Helen Hollingsworth hosts.

Dr. FantaDr. Christopher Fanta is Professor of Medicine at Harvard Medical School and Director of the Partner’s Asthma Center at Brigham and Women’s Hospital in Boston.
Dr. O'DellDr. James O'Dell is Professor of Internal Medicine, Chief of the Section of Rheumatology at the University of Nebraska Medical Center, and Director of the Rheumatoid Arthritis Investigative Network.

Segment on spirometry and asthma diagnosis (Dr. Fanta):

  1. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017; 317:269.

Segment on baricitinib for the treatment of rheumatoid arthritis (Dr. O'Dell):

  1. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376:652.
  2. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior d5isease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017; 69:506.

Christopher H Fanta, MD Nothing to disclose

James R O'Dell, MD Consultant/Advisory Boards: Abbvie [Rheumatoid arthritis (TNF inhibitor)]; Lilly [Rheumatoid arthritis (JAK kinase inhibitor)]; BMS [Rheumatoid arthritis (abatacept)]; GlaxoSmithKline [Rheumatoid arthritis (anti-IL-6)]; Medac [Rheumatoid arthritis (methotrexate)].

Scalp cooling and alopecia from chemotherapy; Immunotherapy for stinging insect hypersensitivity

Date Released: May 3 2017

This episode features Dr. Hope Rugo, discussing the use of a scalp-cooling device to prevent hair loss after chemotherapy in breast cancer patients; and Dr. David Golden, discussing the joint practice parameter on immunotherapy for stinging insect hypersensitivity. Dr. Nancy Sokol hosts.

Dr. RugoDr. Hope Rugo is Clinical Professor in the Department of Medicine at the University of California, San Francisco, and director of the breast oncology clinical trials program at UCSF.
Dr. GoldenDr. David Golden is Associate Professor of Medicine at the Johns Hopkins University School of Medicine.

Segment on scalp hypothermia (Dr. Rugo):

  1. Rugo HS, Klein P, Melin SA, et al. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA 2017; 317:606.
  2. Nangia J, Wang T, Osborne C, et al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA 2017; 317:596.

Segment on stinging insect hypersensitivity (Dr. Golden):

  1. Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol 2017; 118:28.

Hope S Rugo, MD Nothing to disclose

David B Golden, MD Grant/Research/Clinical Trial Support: Genentech [Asthma (Omalizumab)]. Speaker's Bureau: Genentech [Asthma (Omalizumab)]; Stallergenes/Greer [Allergic rhinitis (Sweet vernal, orchard, perennial rye, Timothy, and Kentucky blue grass mixed pollens allergen extract)].

Duration of Zika virus detection in body fluids; Underdosing of direct oral anticoagulants

Date Released: Apr 19 2017

This podcast features Dr. Martin Hirsch, discussing persistence of Zika virus in body fluids; and Dr. Mark Crowther, discussing underdosing of direct oral anticoagulants (DOACs). Dr. Jennifer Tirnauer hosts.

Standard dosing of direct oral anticoagulants table in UpToDate (referenced in the segment on underdosing of DOACs)

Listen to the full podcast by pressing the Play Button below, or jump to the segment on duration of Zika virus in body fluids, or the segment on underdosing of DOACs.

Dr. HirschDr. Martin Hirsch is Professor of Medicine at the Harvard Medical School, Professor of Infectious Diseases and Immunology at the Harvard School of Public Health, and Senior Physician in Infectious Diseases at Massachusetts General Hospital in Boston.
Dr. CrowtherDr. Mark Crowther is Professor and Chair of the Department of Pathology at McMaster University in Ontario.

Segment on duration of Zika virus in body fluids (Dr. Hirsch):

  1. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika Virus in Body Fluids - Preliminary Report. N Engl J Med 2017.

Segment on underdosing of DOACs (Dr. Mark Crowther):

  1. Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017; 117:382.

Martin S Hirsch, MD Nothing to disclose.

Mark Crowther, MD, MSc Consultant/Advisory Boards: Portola, Boehringer-Ingelheim [anticoagulation reversal (andexanet, idarucizumab]).

Treatment for acute otitis media in young children; Tenofovir alafenamide for chronic hepatitis B

Date Released: Apr 5 2017

This podcast features Dr. Sheldon Kaplan, discussing the duration of antibiotic treatment in young children with acute otitis media; and Dr. Anna Lok, discussing the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Dr. Jennifer Mitty hosts.

Listen to the full podcast by pressing the Play Button below, or jump to the segment on acute otitis media, or the segment on tenofovir alafenamide.

Dr. KaplanDr. Sheldon Kaplan is Professor of Pediatrics and head of the Pediatric Infectious Disease section at Baylor College of Medicine, as well as Chief of the Infectious Disease service and head of the Department of Pediatric Medicine at Texas Children's Hospital.
Dr. LokDr. Anna Lok is the Alice Lohrman Andrews Research Professor in Hepatology in the Department of Internal Medicine at the University of Michigan in Ann Arbor and the Director of Clinical Hepatology and Assistant Dean for Clinical Research.

Segment on otitis media (Dr. Kaplan):

  1. Hoberman A, Paradise JL, Rockette HE, et al. Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children. N Engl J Med 2016; 375:2446.

Segment on tenofovir alafenamide (Dr. Lok):

  1. Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:185.
  2. Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:196.

Sheldon L Kaplan, MD Grant/Research/Clinical Trial Support: Pfizer [S. pneumoniae (PCV13, Linezolid)]; Cubist [S. aureus (Tedizolid)]; Forest Lab [Osteomyelitis (Ceftaroline)]. Consultant/Advisory Boards: Pfizer [S. pneumoniae (PCV13, Linezolid); S. aureus (vaccine development)]; Theravance [S. aureus (Telavancin)].

Anna SF Lok, MD Grant/Research/Clinical Trial Support: Gilead [HBV/HCV]; Bristol-Myers Squibb [HCV]; Merck [HCV]. Consultant/Advisory Boards: Gilead (declined honorarium) [HBV/HCV]; Tekmira [HBV (Preclinical studies)].

Pages